Evaluation of compatibility among artemether, pyrimethamine and sulphadoxine using analytical and isothermal calorimetry techniques
- 106 Downloads
The objective of the present study is to identify interactions and incompatibilities among antimalarial drugs in solid state and solution phase. The potential interactions can affect the chemical nature, the stability and bioavailability of drugs and, consequently, their therapeutic efficacy and safety. Herein, the incompatibility studies were performed on artemether: sulphadoxine/pyrimethamine and their physical and treated binary and ternary mixtures. DSC, FT-IR and PXRD outcomes showed no significant chemical changes in physical mixtures and treated samples with respect to their pure samples. In solid state, no changes in data output (exotherm) was observed during conducting tests in isothermal heat flow among binary and ternary mixtures. In solution phase, more exothermic value of excess energy by calorimetry indicated stronger interaction in ternary mixtures relative to binary mixtures. Current investigation unambiguously connoted that artemether was compatible with pyrimethamine or sulphadoxine in combinations, but their ternary mixtures are not safe if co-formulated.
KeywordsArtemether Compatibility studies Drug interactions Combinations Calorimetry
The financial assistance provided by Indian Council of Medical research, New Delhi, India and Instrumentation assistance by Department of Science Technology (DST), New Delhi are acknowledged gratefully.
Conflict of interest
The authors show no conflict of interest.
- 3.World Health Organization. Position of WHO’s Roll Back Malaria. Department on malaria treatment policy. WHO Position Statement: 3. 2003:1–4. Available at :http://www.who.int/malaria/docs/who_apt_position.htm. Accessed 5 April 2013.
- 4.Yeung S, Vornpinyo WP, Hastings IM, Anne JM, Nicholas JW. Antimalarial drug resistance, artemisinin-based combination therapy, and the contribution of modeling to elucidating policy choices. Am J Trop Med Hyg. 2004;71(2):179–86.Google Scholar
- 6.Zakeri S, , Afsharpad M, Raeisi A, Djadid ND. Prevalence of mutations associated with antimalarial drugs in Plasmodium falciparum isolates prior to the introduction of sulphadoxine-pyrimethamine as first-line treatment in Iran. Malar J. 2007;6:148. doi: 10.1186/1475-2875-6-148.CrossRefGoogle Scholar
- 7.Olliaro PL, Taylor WRJ. Developing artemisinin based drug combinations for the treatment of drug resistant falciparum malaria: a review. J Postgrad Med. 2004;50(1):40–4.Google Scholar
- 8.Meshnick SR, Taylor TE, Kamchonwongpaisan S. Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy. Microbiol Rev. 1996;60(2):301–15.Google Scholar
- 9.Van VM, Brockman A, Gemperli B, Luxemburger C, Gathmann I, Royce C, Slight T, Looareesuwan S, White NJ, Nosten F. Randomized comparison of artemether-benflumetol and artesunate mefloquine in treatment of multidrug-resistant falciparum malaria. Antimicrob Agents Chemother. 1998;42:135–9.Google Scholar
- 10.Von Seidlein L, Bojang K, Jones P, Jaffar S, Pinder M, Obaro S, Doherty T, Haywood M, Snounou G, Gemperli B, Gathmann I, Royce C, McAdam K, Greenwood B. A randomized controlled trial of artemether/benflumetol, a new antimalarial and pyrimethamine/sulfadoxine in the treatment of uncomplicated falciparum malaria in African children. Am J Trop Med Hyg. 1998;58:638–44.Google Scholar